BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Sunday, February 15, 2026
Home
»
Newsletters
» BioWorld
BioWorld
Dec. 14, 2009
View Archived Issues
Ocrelizumab Hits Endpoint in RA Trial; Safety Questions Remain
Roche subsidiary Genentech Inc. and Biogen Idec Inc. said their first Phase III trial with anti-CD20 antibody ocrelizumab achieved its primary endpoint of improving ACR20 scores in rheumatoid arthritis patients. (BioWorld Today)
Read More
Dendreon: $356M Sale to Make Provenge, Gear Up for Launch
Read More
Genentech Pact Kaput, SeaGen Revs Effort with Lead Candidate
Read More
MiR-206 Affecting Nerve-Muscle Connection to Slow Down ALS
Read More
Universal Vaccine: 'End-Game' Pursuit to Counter Flu Pandemic
Read More
Other News To Note
Read More
Clinic Roundup
Read More
Bench Press
Read More
